[EN] MODIFIED ISOINDOLINONES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS<br/>[FR] ISOINDOLINONES MODIFIÉES EN TANT QU'INHIBITEURS DE GLUCOSYLCÉRAMIDE SYNTHASE
申请人:MERCK SHARP & DOHME
公开号:WO2022115301A1
公开(公告)日:2022-06-02
The present invention relates to compounds of Formula (I): and pharmaceutically acceptable salts or prodrug thereof. The present invention also relates to compositions comprising at least one compound of Formula (I), and methods of using the compounds of Formula (I) for treatment or prophylaxis of lysosomal storage diseases, neurodegenerative disease, cystic disease, cancer, or a diseases or disorders associated with elevated levels of glucosylceramide (GlcCer), glucosylsphingosine (GlcSph) and/or other glucosylceramide-based glycosphingolipids (GSLs).